

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF      ART UNIT: 1618  
RIGASSI-DIETRICH, PETRA GISELA ET AL.      EXAMINER: VU, JAKE MINH  
INTERNATIONAL APPLICATION NO: PCT/EP2005/002798  
FILED: MARCH 16, 2005  
U.S. APPLICATION NO: 10/590398  
35 USC §371 DATE: AUGUST 23, 2006  
FOR: GALENIC FORMULATIONS OF ORGANIC COMPOUNDS

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:


Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-9587

Date: 8/17/11

Respectfully submitted,



---

Daniel Woods  
Attorney for Applicant  
Reg. No. 59,864